GlassScriptPhysician profile
Mark W Delbello
NPI 1548203300
$6,150.75
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,657 · 2020: $993 · 2021: $1,949 · 2022: $1,549 · 2023: $3.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,069.80 | 2019-2022 | |
| Lilly USA, LLC | $891.57 | 2019-2022 | |
| Novo Nordisk INC | $699.43 | 2019-2022 | |
| Abbvie INC. | $489.97 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $444.80 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $429.52 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $389.51 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $281.74 | 2019-2022 | |
| Pfizer INC. | $255.65 | 2019-2022 | |
| Amgen INC. | $233.91 | 2019-2022 | |
| Abbott Laboratories | $164.50 | 2020-2022 | |
| Glaxosmithkline, LLC. | $117.65 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.69 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $87.55 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $57.51 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $45.34 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $43.02 | 2021-2022 | |
| Daiichi Sankyo INC. | $36.23 | 2019 | |
| Corcept Therapeutics | $29.77 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $28.47 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.29 | 2022 | |
| Astellas Pharma US INC | $27.12 | 2021 | |
| Currax Pharmaceuticals LLC | $25.70 | 2020 | |
| Allergan, INC. | $25.66 | 2020 | |
| Esperion Therapeutics, INC. | $25.29 | 2021 | |
| Antares Pharma, INC. | $23.30 | 2022 | |
| Paratek Pharmaceuticals, INC. | $22.81 | 2022 | |
| Dexcom, INC. | $19.10 | 2021 | |
| Insulet Corporation | $14.38 | 2022 | |
| Horizon Therapeutics Plc | $12.77 | 2021 | |
| Shire North American Group INC | $12.05 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.57 | 2019 | |
| Travere Therapeutics, INC. | $3.08 | 2023 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$12,040.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Delbello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.